# Efdamrofusp Alfa (IBI302)

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/efdamrofusp-alfa-ibi302
Canonical HTML page: https://getbiobrief.com/entity/efdamrofusp-alfa-ibi302

## Timeline

- **2026-Q4 (estimated)**: NDA Submission — Anticipated filing of the New Drug Application with the NMPA.
- **2026-03-24**: Primary Endpoint Met — Innovent announces positive top-line results from the Phase 3 STAR study.
- **2023-03**: STAR Study Initiation — Commencement of the Phase 3 registration trial across multiple sites in China.
- **2021-09**: Phase 2 Completion — Phase 2 data showed promising safety and efficacy in nAMD patients.

## Recent coverage (1 stories)

### Innovent's IBI302 Hits Phase 3 Goal, Pioneering Extended nAMD Care in China
2026-03-24 01:45:29 · Sentiment: Strongly positive · Impact: 8/10 · Sources: 2

Innovent Biologics' IBI302 (efdamrofusp alfa) successfully met its primary endpoint in the Phase 3 STAR registration trial for neovascular age-related macular degeneration. As the first domestically developed extended-interval treatment in China, it represents a significant shift toward reducing the injection burden for millions of patients.
Full story: https://getbiobrief.com/story/innovent-ibi302-phase-3-namd-success

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.